Eli Lilly Lowers Price of Zepbound Obesity Drug to Improve Access
Eli Lilly has announced a price reduction for its obesity drug Zepbound, aiming to make the medication more affordable for U.S. patients. The lower prices apply to single-dose vials available through Lilly’s direct-to-consumer platform, LillyDirect.
Starting December 1, patients paying cash with a valid prescription can buy Zepbound vials for $299 to $449 per month, depending on the dose. Previously, these prices ranged from $349 to $499 per month. The list price of Zepbound before any discounts or rebates was $1,086 per month.
The move comes as demand grows for weight-loss treatments and competition increases among pharmaceutical companies. Shares of Eli Lilly fell slightly following the price announcement.
Zepbound is a prescription drug developed by Eli Lilly for weight loss and obesity treatment.
Patients in the U.S. with a valid prescription who pay cash on LillyDirect are eligible for the new prices.
The price was lowered to make the drug more affordable and widen access as demand and competition in the weight-loss drug market increase.
Reuters
CNBC
Bloomberg Markets and Finance
Forbes
Schaeffers Research
Proactive Investors
Investopedia
CNBC Television